Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma-Reference-Cited by-同舟云学术

Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma

Published:2021-10-20 Issue:2 Volume:101 Page:335-340
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Krishnan Mridula^ORCID,Bociek R. Gregory,Fanale Michelle,Iyer Swaminathan P.,Lechowicz Mary Jo,Bierman Philip J.,Armitage James O.,Lunning Matthew,Kallam Avyakta,Vose Julie M.

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-021-04692-9.pdf

Reference24 articles.

1. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL et al (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 263(5151):1281–1284

2. Tsukasaki K, Tsushima H, Yamamura M, Hata T, Murata K, Maeda T et al (1997) Integration patterns of HTLV-I provirus in relation to the clinical course of ATL: frequent clonal change at crisis from indolent disease. Blood 89(3):948–956

3. Rüdiger T, Geissinger E, Müller-Hermelink HK (2006) ‘Normal counterparts’ of nodal peripheral T-cell lymphoma. Hematol Oncol 24(4):175–180

4. Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E et al (2006) Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 24(16):2472–2479

5. Vose JM, Weisenburger DD, Armitage JO et al (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26(25):4124–4130

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Burning mouth in oncology care: a systematic review;Supportive Care in Cancer;2024-02-20

2. Clinical Experience on Proteasome Inhibitors in Cancer;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

3. Peripheral T-Cell Lymphomas: Therapeutic Approaches;Cancers;2022-05-08